Try our Advanced Search for more refined results

Price Hike Not Shkreli's Only Antitrust Woe, Experts Argue

By Dani Kass (August 8, 2017, 6:43 PM EDT) -- While public outrage against the newly convicted Martin Shkreli has largely focused on his 5,000 percent price hike for the drug Daraprim, three pharmaceutical law experts say the Turing Pharmaceuticals founder's real problem could be that he limited the distribution network of the antiparasitic drug in a likely illegal move to block generic competition....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Attached Documents

Related Sections

Companies

Government Agencies

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!